He Y - Search Results

1

Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.

Li T, Xie J, He Y, Fan H, Baril L, Qiu Z, Han Y, Xu W, Zhang W, You H, Zuo Y, Fang Q, Yu J, Chen Z, Zhang L. Li T, et al. Among authors: he y. PLoS One. 2006 Dec 20;1(1):e24. doi: 10.1371/journal.pone.0000024. PLoS One. 2006. PMID: 17183651 Free PMC article.

2

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.

Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. Du L, et al. Among authors: he y. Vaccine. 2007 Apr 12;25(15):2832-8. doi: 10.1016/j.vaccine.2006.10.031. Epub 2006 Oct 30. Vaccine. 2007. PMID: 17092615 Free PMC article.

3

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.

He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L. He Y, et al. J Biol Chem. 2008 Apr 25;283(17):11126-34. doi: 10.1074/jbc.M800200200. Epub 2008 Feb 26. J Biol Chem. 2008. PMID: 18303020 Free article. Clinical Trial.

4

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.

Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Cao Z, et al. Among authors: he y. Virol J. 2010 Nov 4;7:299. doi: 10.1186/1743-422X-7-299. Virol J. 2010. PMID: 21047436 Free PMC article.

5

In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Liu Z, Shan M, Li L, Lu L, Meng S, Chen C, He Y, Jiang S, Zhang L. Liu Z, et al. Among authors: he y. J Biol Chem. 2011 Feb 4;286(5):3277-87. doi: 10.1074/jbc.M110.199323. Epub 2010 Nov 23. J Biol Chem. 2011. PMID: 21098485 Free PMC article.

6

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Liu L, Xie J, Sun J, Han Y, Zhang C, Fan H, Liu Z, Qiu Z, He Y, Li T. Liu L, et al. Among authors: he y. Scand J Infect Dis. 2011 Jul;43(6-7):515-21. doi: 10.3109/00365548.2011.560184. Epub 2011 Mar 2. Scand J Infect Dis. 2011. PMID: 21366405

7

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.

Zhu Y, Yu D, Han Y, Yan H, Chong H, Ren L, Wang J, Li T, He Y. Zhu Y, et al. Among authors: he y. Sci Adv. 2020 Nov 6;6(45):eabc9999. doi: 10.1126/sciadv.abc9999. Print 2020 Nov. Sci Adv. 2020. PMID: 33036961 Free PMC article.

8

SARS vaccine development.

Jiang S, He Y, Liu S. Jiang S, et al. Among authors: he y. Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219. Emerg Infect Dis. 2005. PMID: 16022774 Free PMC article. Review.

9

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng BJ. Du L, et al. Among authors: he y. J Immunol. 2008 Jan 15;180(2):948-56. doi: 10.4049/jimmunol.180.2.948. J Immunol. 2008. PMID: 18178835 Free PMC article.

10

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.

Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y. Chong H, et al. Among authors: he y. PLoS One. 2012;7(3):e32599. doi: 10.1371/journal.pone.0032599. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403678 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37,331 results

Search Page